Pharmanutra

Regulatory Filings • Oct 21, 2021

Informazione Regolamentata n. 20106-50-2021		Data/Ora Ricezione 21 Ottobre 2021 07:45:21	MTA - Star
Societa'	:	PHARMANUTRA
Identificativo Informazione Regolamentata	:	153195
Nome utilizzatore	:	PHARMANUTRAN02 - Lacorte Roberto
Tipologia	:	REGEM
Data/Ora Ricezione	:	21 Ottobre 2021 07:45:21
Data/Ora Inizio Diffusione presunta	:	21 Ottobre 2021 07:45:22
Oggetto	:	PR - PHARMANUTRA Cetilar patent in India
Testo del comunicato

Vedi allegato.

PHARMANUTRA S.P.A. OBTAINS THE GRANT OF CETILAR® PROCESS PATENT IN INDIA

The Indian Patents Office has granted a process patent for the production of Cetylated Fatty Acids (CFAs), the innovative functional ingredient contained in all the products in the Cetilar® line.

Pisa, 21 October 2021 – PharmaNutra S.p.A. (MTA; Ticket PHN), a company specialising in mineral- and iron-based nutritional supplements and medical devices for muscles and joints, has been granted a process patent in India for the production of Cetylated Fatty Acids (CFAs).

The patent, granted with number 374473, consolidates intellectual property rights for the production of Cetylated Fatty Acids (CFAs), the functional ingredient contained in the Cetilar® -branded topical formulations for the treatment and prevention of articular problems, such as osteoarthritis, various types of articular, muscular or tendon pain, pathologies arising from articular trauma and degenerative articular conditions such as arthrosis, gonarthrosis and coxarthrosis.

The process patent granted in India comes a few months after the same certification was granted in China, further consolidating the PharmaNutra Group's international development projects in Asia, where it already distributes CFA-based products through its partnership with the Thai company American Taiwan Biopharm Co. (ATB), which has successfully marketed the Cetilar® products in Thailand since 2019 and will begin marketing them in Malaysia and Singapore in early 2022.

"Obtaining the Cetilar process patent in India gives a powerful boost to our presence in the East, after China. This is a truly exceptional result, since we're talking about a country with almost 1.4 billion inhabitants, a market with unlimited potential that we cannot wait to explore, backed by the outstanding potential of our patents and products. With this new step, PharmaNutra's international expansion, in parallel with its growth in Italy, continues to be a source of great pride and satisfaction," said PharmaNutra S.p.A. Chairman Andrea Lacorte.

Thanks to the development of patents based on complex of highly concentrated Cetylated Fatty Acids (CFAs), PharmaNutra S.p.A. is now considered one of the top emerging players on the market for medical devices for muscle health and rehabilitation of joint capacity. It already operates in eight countries with its own brand Cetilar® .

PharmaNutra S.p.A.

Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra, established in 2003, develops unique dietary supplements and innovative medical devices, overseeing the entire production process from the proprietary raw materials to the finished product. PharmaNutra is the leading producer, with the SiderAL® trademark, of iron-based nutritional supplements, a field where it holds important patents on Sucrosomial® Technology and is regarded as one of the top emerging players in medical devices for the rehabilitation of joint capacity thanks to the Cetilar® brand. The effectiveness of its products has been demonstrated by extensive scientific evidence, including more than 120 published papers. In Italy, sales are conducted through a network of more than 160 medical representatives, who also handle exclusive marketing of PharmaNutra products to pharmacies all over the country. International sales in more than 50 countries are managed through 37 partners selected from top pharmaceutical companies. Over the years, the Group has developed a specific intellectual property production and management strategy, based on integrated management of all components: proprietary raw materials, patents, trademarks and clinical data.

PharmaNutra.it

For further information:

Via Delle Lenze, 216/b - 56122 Pisa Tel. +39 050 7846500 investorrelation@PharmaNutra.it

Internal Press Office press@calabughi.com

PharmaNutra S.p.A. Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan Tel. +39 02 83635708

Matteo Russo mrusso@sprianocommunication.com Cristina Tronconi ctronconi@sprianocommunication.com